This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
Timeframe: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From time of Informed consent to 30 days post end of treatment
Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)
Timeframe: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)
AstraZeneca Clinical Study Information Center